Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Payables (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Payables data on record, last reported at $45.2 million in Q3 2025.

  • For Q3 2025, Payables fell 29.97% year-over-year to $45.2 million; the TTM value through Sep 2025 reached $45.2 million, down 29.97%, while the annual FY2024 figure was $65.5 million, 10.96% down from the prior year.
  • Payables reached $45.2 million in Q3 2025 per FBIO's latest filing, down from $48.6 million in the prior quarter.
  • Across five years, Payables topped out at $108.4 million in Q1 2023 and bottomed at $10.5 million in Q3 2021.
  • Average Payables over 5 years is $72.8 million, with a median of $73.6 million recorded in 2023.
  • Peak YoY movement for Payables: plummeted 79.53% in 2021, then soared 791.46% in 2022.
  • A 5-year view of Payables shows it stood at $91.5 million in 2021, then rose by 9.75% to $100.4 million in 2022, then decreased by 26.73% to $73.6 million in 2023, then dropped by 10.96% to $65.5 million in 2024, then crashed by 31.04% to $45.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $45.2 million in Q3 2025, $48.6 million in Q2 2025, and $66.3 million in Q1 2025.